Cargando…

A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma

BACKGROUND: Abundant collagen deposition is a hallmark of pancreatic ductal adenocarcinomas (PDACs). This study clarified the interactive relationship between tumor-stromal collagen, molecular and immune characteristics, and tumor pr ogression in human PDAC. METHODS: We performed a comprehensive exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashina, Shigeto, Masuda, Atsuhiro, Yamakawa, Kohei, Hamada, Tsuyoshi, Tsujimae, Masahiro, Tanaka, Takeshi, Toyama, Hirochika, Sofue, Keitaro, Shiomi, Hideyuki, Sakai, Arata, Kobayashi, Takashi, Abe, Shohei, Gonda, Masanori, Masuda, Shigeto, Inomata, Noriko, Uemura, Hisahiro, Kohashi, Shinya, Nagao, Kae, Harada, Yoshiyuki, Miki, Mika, Juri, Noriko, Irie, Yosuke, Kanzawa, Maki, Itoh, Tomoo, Inoue, Jun, Imai, Toshio, Fukumoto, Takumi, Kodama, Yuzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522520/
https://www.ncbi.nlm.nih.gov/pubmed/37477731
http://dx.doi.org/10.1007/s00535-023-02020-8
Descripción
Sumario:BACKGROUND: Abundant collagen deposition is a hallmark of pancreatic ductal adenocarcinomas (PDACs). This study clarified the interactive relationship between tumor-stromal collagen, molecular and immune characteristics, and tumor pr ogression in human PDAC. METHODS: We performed a comprehensive examination using an integrative molecular pathological epidemiology database on 169 cases with resected PDAC . The amount of tumor-stromal collagen was quantified through digital imaging analysis for Elastica van Gieson-stained whole-section tumor slides. We analyzed the association of tumor-stromal collagen with gene alterations (KRAS, TP53, CDKN2A/p16, and SMAD4), immune parameters (CD4(+) tumor-infiltrating lymphocytes [TILs], CD8(+) TILs, FOXP3(+) TILs, and tertiary lymphoid structures), and patient prognosis. RESULTS: Low amounts of tumor-stromal collagen were associated with poor differentiation (multivariable OR = 3.82, 95%CI = 1.41–12.2, P = 0.008) and CDKN2A/p16 alteration (OR [95%CI] = 2.06 [1.08–4.02], P = 0.03). Tumors with low collagen levels had shorter overall survival (HR [95%CI] = 2.38 [1.59–3.56], P < 0.0001). In the S-1 and gemcitabine (GEM) treatment groups, low tumor-stromal collagen was linked to poor prognosis of patients with PDAC (S-1 group: multivariable HR [95%CI] = 2.76 [1.36–5.79], P = 0.005; GEM group: multivariate HR [95%CI] = 2.91 [1.34–6.71], P = 0.007). Additionally, low amounts of tumor-stromal collagen were also linked to low levels of CD4(+) TILs (P = 0.046), CD8(+) TILs (P = 0.09), and tertiary lymphoid structures (P = 0.001). CONCLUSIONS: Tumor-stromal collagen deposition may play a crucial role in modulating tumor-immune microenvironment and determining response to adjuvant chemotherapy and patient survival outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-023-02020-8.